# iBio Reports Preclinical Data Showing Enhanced Fat Loss with IBIO-610 Combo

- URL: https://stocks.freetheai.org/news/ibio-reports-preclinical-data-showing-enhanced-fat-loss-with-ibio-610-combo-9fdfba
- Published: 2026-10-13T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:IBIO](https://stocks.freetheai.org/symbols/NASDAQ-IBIO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Biotechnology firm iBio, Inc. (IBIO) released preclinical trial results demonstrating that combining its experimental drug IBIO-610 with semaglutide produced higher fat-selective weight loss in obese non-human primates. In an eight-week study of six subjects per group, animals treated with the combination lost 93% of their weight as fat compared to 77% for those receiving semaglutide alone. Lean mass loss fell to 6% in the combination group, down from 22% with semaglutide monotherapy.

Preserving lean muscle tissue remains a significant challenge for existing obesity treatments like GLP-1 receptor agonists. Treatment with IBIO-610 also led to a 97% reduction in Activin E at eight weeks, confirming target engagement. Additionally, the drug exhibited a 33.2-day half-life in primates, supporting potential for less frequent dosing schedules.

Following the news, shares of iBio rose 3.70% to $0.9032. The company plans to initiate its first human clinical trials for IBIO-610 in the first half of 2027. Investors will watch for regulatory filings and initial safety findings to determine whether the preclinical performance translates effectively to human patients.

## Key points

- Combining IBIO-610 with semaglutide resulted in 93% fat loss versus 77% with semaglutide alone in an 8-week primate study.
- Lean mass loss decreased to 6% with the combination therapy, compared to 22% for semaglutide monotherapy.
- IBIO-610 achieved a 97% reduction in Activin E at week eight and demonstrated a 33.2-day half-life in primates.
- iBio plans to start first-in-human clinical trials for IBIO-610 in the first half of 2027.

## Questions and answers

### What were the results of iBio's IBIO-610 study?

In an 8-week study on obese primates, combining IBIO-610 with semaglutide resulted in 93% of lost weight coming from fat, compared to 77% with semaglutide alone. Lean mass loss was reduced to 6% from 22%.

### When will human trials begin for IBIO-610?

iBio plans to launch first-in-human clinical trials for IBIO-610 during the first half of 2027.

### How did iBio stock react to the news?

iBio, Inc. shares gained 3.70% following the announcement, trading at approximately $0.9032.